Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.

Titel:: Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.
Dokumenttyp:: Journal Article; Review
Autor(en):: Ettl, Johannes
Abstract:: Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.
Zeitschriftentitel:: Breast Care (Basel)
Jahr:: 2016
Band / Volume:: 11
Heft / Issue:: 3
Seitenangaben Beitrag:: 174-6
Sprache:: eng
Volltext / DOI:: doi:10.1159/000447417
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/27493616
Print-ISSN:: 1661-3791
TUM Einrichtung:: Frauenklinik und Poliklinik
BibTeX

Vorkommen: